1. Home
  2. BTDR vs HRMY Comparison

BTDR vs HRMY Comparison

Compare BTDR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTDR

Bitdeer Technologies Group

HOLD

Current Price

$8.09

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$27.70

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTDR
HRMY
Founded
2021
2017
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BTDR
HRMY
Price
$8.09
$27.70
Analyst Decision
Strong Buy
Buy
Analyst Count
10
10
Target Price
$25.10
$46.70
AVG Volume (30 Days)
8.7M
1.1M
Earning Date
02-12-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.97
EPS
N/A
2.71
Revenue
N/A
$868,453,000.00
Revenue This Year
$72.51
$19.87
Revenue Next Year
$40.84
$12.49
P/E Ratio
N/A
$10.32
Revenue Growth
N/A
21.51
52 Week Low
$6.84
$25.52
52 Week High
$27.80
$40.87

Technical Indicators

Market Signals
Indicator
BTDR
HRMY
Relative Strength Index (RSI) 42.21 33.54
Support Level $7.30 $27.66
Resistance Level $14.74 $28.99
Average True Range (ATR) 0.61 0.74
MACD 0.26 0.22
Stochastic Oscillator 32.62 34.04

Price Performance

Historical Comparison
BTDR
HRMY

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: